The association of glycogen synthase kinase-3beta (GSK-3β) gene polymorphism with kidney function in long-term lithium-treated bipolar patients by Janusz K Rybakowski et al.
Rybakowski et al. International Journal of Bipolar Disorders 2013, 1:8
http://www.journalbipolardisorders.com/content/1/1/8RESEARCH Open AccessThe association of glycogen synthase kinase-3beta
(GSK-3β) gene polymorphism with kidney function
in long-term lithium-treated bipolar patients
Janusz K Rybakowski1*, Maria Abramowicz1, Aleksandra Szczepankiewicz2,3, Michal Michalak4, Joanna Hauser2
and Stanislaw Czekalski5Abstract
Background: Most bipolar patients experience a reduction in urinary concentrating ability within a few weeks of
starting lithium treatment. This phenomenon may be connected with the effect of lithium on the glycogen
synthase kinase-3beta (GSK-3β) present in the renal tubules. The GSK-3β gene is located on chromosome 3q13 and
possesses a functional -50 C/T polymorphism. In the present study, we estimated this polymorphism in a group of
long-term lithium-treated patients and assessed its association with various parameters of kidney function, including
novel markers of kidney injury such as serum neutrophil gelatinase-associated lipocalin (NGAL) and urinary beta2-
microglobulin (β2-MG).
Methods: The study comprised 78 patients with bipolar mood disorder (25 males, 53 females), aged 36 to 82
(60 ± 11) years. The mean duration of bipolar illness was 6 to 50 (24 ± 10) years, and the patients have been
receiving lithium for 5 to 38 (16 ± 9) years. All the patients had the following features, regarded as the phenotypes
of kidney functions measured: urine examination for specific gravity evaluation, serum creatinine concentration, and
estimated glomerular filtration rate (eGFR) evaluation, as well as the serum concentrations of NGAL and urinary
β2-MG. Genotyping of GSK-3β gene -50 C/T polymorphism was done by polymerase chain reaction analysis.
Results and discussion: Thirty-four patients (6 males, 28 females) had the T/T genotype, 37 patients (16 males, 21
females) had the T/C genotype, and 7 patients (3 males, 4 females) had the C/C genotype. Patients homozygous for C
allele had significantly higher urine specific gravities (1.019 ± 0.008) compared to the remaining genotypes (1.013 ±
0.007) (p = 0.035), with no influence of the duration of lithium treatment. Other parameters of kidney function (serum
creatinine, eGFR, serum NGAL, and urinary β2-MG levels) were not different between genotypes and, again, were not
affected by the duration of lithium treatment. There was no correlation between urine specific gravity and other kidney
function parameters. The results of our study indicate that the GSK-3β genotype may be connected with lithium-
induced impairment of renal concentrating ability in long-term lithium-treated bipolar patients. Limitations of the study
include small size of the sample, small number of C/C genotype patients, and a lack of multiple testing analysis of
genotypic differences in various measures of kidney function.
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Lithium is the most effective therapeutic modality for
the prevention of manic and depressive recurrences in
bipolar disorder (Rybakowski 2011). Since its intro-
duction for this purpose (Hartigan 1963), considerable
concerns have been aroused about a possible negative
effect of lithium on kidney function. Evidence of this
effect has accumulated from patients receiving lithium
for 10 years or more.
The most frequent renal lithium effect is a decrease in
urinary concentrating ability, which clinically manifests
itself by polyuria and polydipsia of various intensities. It
may affect 30% to 80% of patients on long-term lithium
therapy and may occur as early as after several weeks of
lithium administration (Schou and Vestergaard 1988). In
some patients receiving lithium for 10 to 20 years,
chronic interstitial nephropathy may develop, which
results in increased serum creatinine and a reduction in
the glomerular filtration rate (GFR). The duration of
lithium treatment is the main predisposing factor for
nephropathy which, in a small proportion of patients,
can result in end-stage renal disease (Presne et al. 2003).
In recent years, some novel markers of kidney injury
have been identified. Among these, the serum level of
the neutrophil gelatinase-associated lipocalin (NGAL)
may be a biomarker for glomerular filtration and
correlates with the severity of the damage in patients
with chronic kidney disease. Another marker is beta2-
microglobulin (β2-MG), the concentration of which in
the urine may be correlated with the degree of tubular
reabsorption impairment (Lisowska-Myjak 2010; Adiyanti
and Loho 2012).
Glycogen synthase kinase-3beta (GSK-3β) is a pluripo-
tent kinase involved in a number of cell functions. The
inhibition of GSK-3β by lithium has been discovered
nearly two decades ago (Stambolic et al. 1996). From a
bipolar disorder perspective, the most important func-
tion of GSK-3β may be its role in synaptic plasticity,
apoptosis, and the circadian cycle (Bradley et al. 2012;
Iitaka et al. 2005). Therefore, the effect on GSK-3β could
be responsible for lithium's therapeutic action in bipolar
illness, including neuroprotection and circadian regula-
tion (Gould and Manji 2005). In the renal tubules, GSK-
3β controls water transport via aquaporin 2 (AQ2) and
sodium transport via the epithelial sodium channel.
Lithium, unlike sodium, is not transported out of the
cells of collecting ducts by the Na+, K+, ATPase and
may accumulate intracellularly, reaching a concentration
capable of substantially inhibiting GSK-3β. It has been
hypothesized that such a mechanism may underlie the
lithium-induced impairment of urinary concentrating
ability (Grünfeld and Rossier 2009).
The GSK-3β gene is located on chromosome 3q13 and
possesses a functional -50 C/T promoter polymorphism(rs334558), where a wild T allele has significantly higher
transcriptional activity than its mutant C allele (Kwok
et al. 2005). In most studies on the association of this
polymorphism with the effect of lithium treatment, a
better effect has been demonstrated for carriers of C
allele of this polymorphism. Such a connection was
found in two studies on lithium prophylactic efficacy
(Benedetti et al. 2005; Lin et al. 2013). However, in our
paper (Szczepankiewicz et al. 2006), we were not able to
confirm this. Adli et al. (2007) reported that carriers of
the C allele showed a significantly better response to
lithium augmentation of antidepressants compared to
patients with the T/T genotype. Recently, Italian investi-
gators have showed an association of the C allele of this
polymorphism with a lithium-induced increase of white
matter in bipolar patients (Benedetti et al. 2013).
We hypothesized that this functional polymorphism of
the GSK-3β gene could also be associated with the degree
of lithium effect on kidney function, including urinary
concentrating ability and also, perhaps, other effects.
Therefore, in this present study, several parameters of kid-
ney function in a group of long-term lithium-treated pa-
tients were assessed in relation to their GSK-3β genotype.
Methods
Patients
The study comprised 78 patients with bipolar mood
disorder (25 males, 53 females), aged 36 to 82 (60 ± 11)
years. The mean duration of bipolar illness was 6 to 50
(24 ± 10) years. Consensus diagnosis by at least two
psychiatrists was made for each patient, according to
DSM-IV criteria (SCID) (First et al. 1996). These patients
have been receiving lithium for 5 to 38 (16 ± 9) years.
The study was approved by the Bioethics Committee,
Poznan University of Medical Sciences, and all the
patients gave their informed consent, after the nature of
the procedures had been fully explained to them.
Measurements of kidney function
The following investigations, regarded for the use of this
study as the phenotypes of kidney function were carried
out: urine examination with specific gravity evaluation
performed in a sample collected after overnight hydro-
penia, serum creatinine concentration, and estimated
GFR (eGFR) evaluation, as well as two markers of kidney
injury: the serum concentration of NGAL and the uri-
nary concentration of β2-MG.
The serum concentration of creatinine was measured
by the enzymatic method with creatininase. The eGFR
was calculated according to the MDRD formula (Kokot
et al. 2011). The NGAL in serum was measured by the
enzyme-linked immunosorbent assay method, and the
β2-MG in urine was assessed by the enzymatic immuno-
assay method.
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The DNA was extracted from 10 ml of EDTA-
anticoagulated whole blood, using the salting out method
(Miller 1988). A 344-bp fragment of the GSK-3β gene was
amplified by polymerase chain reaction (PCR) reaction,
with the set of primers described by Russ (2001), using a
PTC-200 (MJ Research, St. Bruno, Canada) thermal cycler.
The PCR product (4.0 ml) was then digested with AluI
restriction endonuclease (MBI Fermentas, Burlington,
Canada). The uncut PCR product size was 344 bp. After
RFLP analysis, the following alleles were observed: uncut
C allele (127 bp), and for the T allele, the bands of 220 and
124 bp. To confirm the results, the restriction analysis for
the uncut C allele was repeated.
Statistics
The results are presented as the means ± SD for the
whole group of patients and for the two subgroups of
patients: men and women. Comparisons of the sub-
groups were performed by the one-way analysis of vari-
ance (ANOVA) test and by the unpaired t test for the
two groups. The distribution of genotypes according to
the Hardy-Weinberg equilibrium was determined for the
whole group and, additionally, for each gender. The chi-
square test was used for calculating differences in geno-
typic distribution. Any possible association of genotypes
of the GSK-3β gene with parameters of kidney function
was analyzed, also taking into account the duration of
lithium treatment, as a covariant (analysis of covariance).
For correlations, Pearson's linear correlation coefficient
was used. The significance of the correlation coefficient
was checked by Student's t test. All the calculations were
made using the Statistica (StatSoft, Polska) version 10
statistical package. The level of statistical significance
was determined at p < 0.05.
Results
The measurements of kidney function in the whole
group of patients studied, as well as in the male and
female subgroups, are shown in Table 1.
A significantly higher serum creatinine concentration
was found in the male patients than in females (p < 0.001).
This was reflected in a lower eGFR in the male patients, atTable 1 Measurements of kidney function in the patients stud
Urine specific gravity 1,0
Serum creatinine (mg/dl) 0
Estimated glomerular filtration rate (ml/min/1.73 m2)
Serum neutrophil gelatinase-associated lipocalin (ng/ml) 3
Urine beta2-microglobulin (μg/ml) 0
Values are expressed as means ± SD. *p < 0.001, significant difference between mathe level of statistical trend (p = 0.085). Correlation with
the duration of lithium therapy was obtained only in the
group of male patients: a positive correlation with beta2-
microglobulin (p = 0.005) and creatinine concentration
(p = 0.048) and a negative correlation with urinary specific
gravity (p = 0.030).
The genotypic distributions of -50 C/T polymorphism of
the GSK-3β gene in the patients studied, with their Hardy-
Weinberg equilibrium values, are shown in Table 2.
Thirty-four patients (6 males, 28 females) had the T/T
genotype, 37 patients (16 males, 21 females) the T/C
genotype, and 7 patients (3 males, 4 females) the C/C
genotype. The genotypes were in Hardy-Weinberg equi-
librium, both for the whole group as well as for the male
and female subgroups. The T/T genotype was signifi-
cantly less frequent in males, while the T/C genotype
was significantly less frequent in the females (χ2 = 5.05,
p = 0.025).
The analysis of the genotypic differences, in relation to
kidney function, is shown in Table 3. Due to significant
differences in serum creatinine concentration, the ana-
lysis of this parameter was additionally performed sepa-
rately for the male and female subjects.
Patients homozygous for the C allele had significantly
higher urine specific gravity (1.019 ± 0.008) compared to
the remaining genotypes (1.013 ± 0.007) (p = 0.035),
with no influence of the duration of lithium treatment.
Other parameters of kidney function (serum creatinine,
eGFR, NGAL, and urinary β2-MG levels) were not
different between genotypes, irrespective of the duration
of lithium treatment. CC homozygotes had numerically
lower values of serum NGAL and urine β2-MG com-
pared to other genotypes. However, this difference was
not statistically significant.
In this group of patients, there was no correlation
between urine specific gravity and other parameters of
kidney function.
Discussion
The main finding of this study is that lithium-treated
patients homozygous for the C allele have better preserved
function of renal concentrating ability, compared to the
remaining genotypes of this polymorphism, as reflected inied
Total Men Women
N = 78 N = 25 N = 53
13 ± 0.007 1,013 ± 0.008 1,013 ± 0.008
.95 ± 0.25 1.18 ± 0.28 0.83* ± 0.17
71 ± 14 67 ± 18 73 ± 12
00 ± 118 326 ± 112 287 ± 119
.18 ± 0.19 0.20 ± 0.20 0.17 ± 0.18
le and female patients (t test).
Table 2 Genotype distribution in the group of patients
studied with HWE - frequencies and p values
T/T T/C C/C HWE
Total (N = 78) 34 (44%) 37 (47%) 7 (9%) 0.491
Male (N = 25) 6 (24%) 16 (64%) 3 (12%) 0.135
Female (N = 53) 28 (53%) 21* (39.5%) 4 (7.5%) 0.981
*p = 0.025, significant difference between male and female patients as to T/T
vs. T/C distribution (chi-square test). HWE, Hardy-Weinberg equilibrium.
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mean that C allele-bearing patients may be more resilient
to the lithium inhibitory effect on GSK-3β activity in
kidneys.
GSK-3β is an enzyme which has recently gained increa-
sing attention as a signaling molecule in the epithelial cells
of renal tubules as its inhibition may have various conse-
quences. On the one hand, it has been shown that the
inhibition of such a proapoptotic and antiproliferative
signaling factor as GSK-3β could be protective in acute
kidney injury (Dugo et al. 2005). On the other hand, the
inhibition of this enzyme could lead to a disturbance of
water homeostasis in the kidneys, mainly by disturbed
AQ2 regulation of water channels via adenylate cyclase or
the prostaglandin E2 pathway. In the short term, GSK-3β
could disrupt vasopressin signaling in the collecting
duct cells and, in the long term, make the collecting
duct less responsive to the hydro-osmotic effect of
vasopressin (Rao 2012).
As mentioned earlier, other clinical studies in which this
GSK-3β gene polymorphism was estimated have shown a
positive association between possessing the C allele and
lithium therapeutic effects such as the quality of long-
term prophylaxis of bipolar mood disorder (Benedetti
et al. 2005; Lin et al. 2013), augmentation of antidepres-
sants in treatment-resistant depression (Adli et al. 2007),
or lithium-induced increase of white matter in bipolarTable 3 Analysis of genotype differences in relation to kidney
T/T T/C
N = 34 N = 37
Urine specific gravity 1,012 ± 0.007 1,013 ± 0.007 1,01
Serum creatinine, total (mg/dl) 0.89 ± 0.20 0.99 ± 0.28 0.9
Male 1.19 ± 0.25 1.16 ± 0.32 1.2
N = 6 N = 16
Female 0.83 ± 0.12 0.85 ± 0.14 0.8
N = 28 N = 21
Estimated glomerular filtration rate
(ml/min/1.73 m2)
71 ± 13 71 ± 16
Serum neutrophil gelatinase-associated
lipocalin (ng/ml)
288 ± 89 321 ± 142 2
Urine beta2-microglobulin (μg/ml) 0.22 ± 0.24 0.16 ± 0.14 0.1
The p values of the differences in kidney function values are expressed as means ±
patients compared to remaining genotypes combined.patients (Benedetti et al. 2013). The better effect of lithium
in patients with the C allele could be explained by a detri-
mental effect of GSK-3β on brain function and a greater
inhibitory effect of lithium in patients with lower activity
of the enzyme. As to kidney function, an effect of the C
allele on lithium-induced GSK-3β inhibition is more diffi-
cult to explain. In view of the dual effects of GSK-3β
inhibition on kidney cells, it may be hypothesized that, in
C allele homozygotes, a protective effect of this inhibition
prevails, while in other genotypes, such an effect leads
mostly to an impairment of the urinary concentrating abi-
lity. It seems therefore that the mutant C allele of GSK-3β
gene polymorphism may not only be connected with a
better clinical lithium response due to the brain effect of
this drug, but that also it is protective against the lithium
effect on some aspect of kidney function.
In this group of patients, we demonstrated a signifi-
cant relationship of the GSK-3β genotype only with one
aspect of kidney function, the urinary concentrating
ability. We did not find any significant association in the
remaining parameters measured. However, some hint
could come from the numerically lower values of serum
NGAL and urinary β2-MG in the CC homozygotes com-
pared to other genotypes. These values could achieve
statistical significance with a higher number of patients
possessing the C/C genotype.
The main limitation of our study is the small size of the
sample and especially the small number of C/C genotype
patients (9%). Furthermore, a multiple testing analysis was
not applied to genotypic differences in relation to various
measures of kidney function. In such case, after Bonferroni
correction, the main result connected with urine specific
gravity would be insignificant. However, if treating urine
specific gravity as a separate parameter, we believe that
the difference between C/C and other phenotypes com-
bined (1.019 ± 0.008 vs. 1.013 ± 0.007, respectively) is afunction
C/C T/T vs. T/C vs. C/C T/T vs. T/C + C/C T/T + T/C vs. C/C
N = 7 (ANOVA) t test t test
9 ± 0.008 p = 0.052 p = 0.215 p = 0.035
8 ± 0.23 p = 0.448 p = 0.074 p = 0.603
2 ± 0.10 p = 0.939 p = 0.884 p = 0.781
N = 3
0 ± 0.06 p = 0.774 p = 0.772 p = 0.515
N = 4
68 ± 9 p = 0.977 p = 1.000 p = 0.606
48 ± 81 p = 0.441 p = 0436 p = 0.216
3 ± 0.05 p = 0.279 p = 0.162 p = 0.410
SD. Italicized p value indicates urine specific gravity significantly higher in C/C
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our study is the long duration of lithium administration
given to our patients, which allows us to make a true
assessment of the long-term effects of lithium on
kidney function.
Conclusions
The results of our study indicate that the GSK-3β geno-
type may be connected with lithium-induced impairment
of renal concentrating ability in long-term lithium-treated
bipolar patients. This may reflect a putative role of this
enzyme in the mechanisms of water and sodium transport
in the renal tubules. None of the other aspects of kidney
function studied appeared to be influenced by this geno-
type. However, bearing in mind the limitations of our
study, we should regard it as an exploratory one warran-
ting further studies in larger samples.
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